Credit Suisse Says AbbVie’s Humira Patent Cliff Could Provide Momentum to Boost Growth
Credit Suisse has initiated coverage on AbbVie Inc (NYSE:ABBV) with an Outperform rating and a price target of $170. AbbVie stands on…
Analyst Ratings for AbbVie
Analysts have provided the following ratings for AbbVie (NYSE:ABBV) within the last quarter: Bullish Somewhat Bullish Indifferent Somewhat…
10 Health Care Stocks Whale Activity In Today’s Session
This whale alert can help traders discover the next big trading opportunities.
Whales are entities with large sums of money and we track their transactions here at Benzinga on our options activity scanner.
What 8 Analyst Ratings Have To Say About AbbVie
Analysts have provided the following ratings for AbbVie (NYSE:ABBV) within the last quarter: Bullish Somewhat Bullish Indifferent Somewhat…
Societe Generale Downgrades AbbVie to Hold
Societe Generale analyst Justin Smith downgrades AbbVie (NYSE:ABBV) from Buy to Hold.
Control Of Congress Up For Grabs In Midterms: 12 Stocks To Watch
As voters endeavor to select the congressional candidates they believe would best assist the U.S. in navigating through historical issues it is currently facing, investors are wondering what's going to happen to equities.
AbbVie Announces Late-Breaking Results From Phase 2 Exploratory NOVA Trial Of Novel Investigational Neurotoxin AGN-151607 For The Prevention Of Postoperative Atrial Fibrillation In Cardiac Surgery Patients, Primary Endpoint Was Not Met
Primary endpoint was not met for the modified intent-to-treat (mITT) population; however, clinical benefit observed in coronary artery bypass graft (CABG) patients
After FDA, European Agency Limits Use Of Certain JAK Inhibitors Amid Safety Concerns
The European Medicine Agency’s safety committee recommended that a group of JAK inhibitors for chronic inflammatory disorders be only used…
Barclays Maintains Equal-Weight on AbbVie, Lowers Price Target to $155
Barclays analyst Carter Gould maintains AbbVie (NYSE:ABBV) with a Equal-Weight and lowers the price target from $160 to $155.